Apimeds Pharmaceuticals US (APUS) Stock: Buy, Sell, or Hold?
APUS - Apimeds Pharmaceuticals US, Inc.
$3.04
-0.12 (-3.79%)
▼
5d:
-24.75%
30d:
-38.21%
90d:
-51.67%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When APUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: APUS is down 24.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: APUS is down 24.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: APUS is currently trading at $3.04, which is considered slightly low relative to its 30-day fair value range of $2.27 to $5.66.
Technical Outlook: Technically, APUS is in a uptrend. The price is currently testing key support at $3.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, APUS is in a uptrend. The price is currently testing key support at $3.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.27 -
$5.66
Company Quality Score
51/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
68.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-3.8%)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.27 -
$5.66
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.01
Resistance Level
$6.04
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Share & Embed Analysis
Last updated: October 23, 2026 10:49 AM ET
Data refreshes hourly during market hours. Next update: 11:49 AM
Data refreshes hourly during market hours. Next update: 11:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APUS showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |